Progress of clinical research on immunotherapy and antibody-drug conjugates for the treatment of triple-negative breast cancer
10.12173/j.issn.1008-049X.202402077
- VernacularTitle:免疫治疗及抗体偶联药物治疗三阴性乳腺癌的临床研究进展
- Author:
Dan YANG
1
;
Jinxiu WANG
;
Dahua MAO
Author Information
1. 贵州医科大学研究生院(贵阳 550000)
- Keywords:
Triple-negative breast cancer;
Immunotherapy;
Antibody-drug conjugates;
Clinical trials;
Immune checkpoint inhibitors;
Chemotherapy
- From:
China Pharmacist
2024;27(5):901-908
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer(TNBC)is one of the prognosis poorer molecular subtypes of breast cancer with limited conventional treatments,however,it is characterized by a strong immune microenvironmental activity,which provides a certain biological basis for immunotherapy as well as antibody-drug conjugates(ADCs).Nowadays,the combination of immune checkpoint inhibitors and chemotherapy,as well as the successive introduction of ADCs such as sacituzumab govitecan and trastuzumab deruxtecan,has changed the therapeutic pattern of TNBC and provided new ideas for the development of new drugs for TNBC.In this paper,the clinical research progress of immunotherapy and ADCs for the treatment of TNBC is reviewed,in order to provide a reference for the strategy selection of clinical drugs,that is,the future research and development trend.
